CIP
PTGX icon

Cornerstone Investment Partners’s Protagonist Therapeutics PTGX Stock Holding History

Cornerstone Investment Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,634
Closed -$405K – 322
2025
Q4 		$405K Buy
4,634
+2
+0% +$164 0.02% 79
2025
Q3 		$308K Sell
4,632
-348
-7% -$19.8K 0.01% 105
2025
Q2 		$275K Buy
4,980
+3
+0.1% +$144 0.01% 117
2025
Q1 		$241K Sell
4,977
-439
-8% -$18.4K 0.01% 111
2024
Q4 		$209K Sell
5,416
-5
-0.1% -$218 0.01% 189
2024
Q3 		$244K Buy
+5,421
New +$219K 0.01% 146

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Cornerstone Investment Partners's PTGX Position: Q1 2026 in Review

Cornerstone Investment Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 4,634 shares — an estimated $405K sold.

Cornerstone Investment Partners first reported a position in PTGX in Q3 2024 and held it in 6 quarters. The position peaked at $405K in Q4 2025. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Cornerstone Investment Partners reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cornerstone Investment Partners sold 4,634 Protagonist Therapeutics shares in Q1 2026, an estimated $405K.
  • Cornerstone Investment Partners first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 6 quarters.
  • Cornerstone Investment Partners's Protagonist Therapeutics position peaked at $405K in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Cornerstone Investment Partners's 13F filing for Q1 2026, filed 8 May 2026.